Cited by ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy?

Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy DOI

Teresa Amaral, Eftychia Chatziioannou,

A. Nuebling

et al.

European Journal of Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 115372 - 115372

Published: April 1, 2025

More than 80 % of patients with melanoma are diagnosed without nodal metastasis, but most those who relapse or die from initially as low risk early-stage. Here we investigate the ability Merlin Assay to stratify did not undergo sentinel lymph node biopsy (SLNB) for their recurrence. 930 clinical stage I/II primary cutaneous University Tuebingen between 2000 and 2020 were analyzed. None included underwent SLNB. The combines patient age at diagnosis, Breslow thickness, gene expression eight specific genes tumor. Risk output labels High Low Risk. Clinicopathological profile (CP-GEP) identified 879 51 10-year RFS (HR 20.07; p < 0.001) DMFS 19.39; significantly higher in CP-GEP versus patients. Similar results observed MSS 35.85; 0.001). analysis lentigo maligna acral lentiginous showed that performance assay was independent histological subtypes. This study shows has potential early-stage SLNB based on Patients have a better long-term survival. be promising guiding referral may support care by optimizing personalized treatment plans surveillance regimens.

Language: Английский

Citations

Nodal Management in Melanoma DOI

Derek Effiom,

Sonia Cohen

Surgical Oncology Clinics of North America, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Citations

Cutaneous melanoma DOI

Alpaslan Tasdogan, Ryan J. Sullivan, Alexander Katalinic

et al.

Nature Reviews Disease Primers, Journal Year: 2025, Volume and Issue: 11(1)

Published: April 3, 2025

Language: Английский

Citations

Quoi de neuf en oncodermatologie ? DOI

Elisa Funck‐Brentano

Annales de Dermatologie et de Vénéréologie - FMC, Journal Year: 2024, Volume and Issue: 4(8), P. 8S36 - 8S44

Published: Nov. 27, 2024

Citations

ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy? DOI

Thomas E. Pennington, John F. Thompson, Alexander H. R. Varey

et al.

Annals of Surgical Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 27, 2024

Language: Английский

Citations